Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting [Yahoo! Finance]
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: Yahoo! Finance
BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from two real-world studies evaluating the economic benefits of EXPAREL ® (bupivacaine liposome injectable suspension) in orthopaedic procedures, including total knee arthroplasty (TKA) and spinal fusion. In both studies, EXPAREL was associated with lower total cost of care compared with ropivacaine in one study and standard of care options (non-LB) in the other, with reductions observed in both outpatient and inpatient surgical settings. The data will be presented at the Orthopaedic Research Society (ORS) 2026 Annual Meeting taking place March 27–31 in Charlotte, North Carolina. Briefly, the analyses include two propensity score-matched cohort studies evaluating outcomes on surgery day and throughout 30 days of follow-up in commercial and Medi
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026GlobeNewswire
- Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty ProceduresGlobeNewswire
- Pacira BioSciences (PCRX) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual MeetingGlobeNewswire
PCRX
Earnings
- 2/26/26 - Miss
PCRX
Sec Filings
- 4/17/26 - Form PREC14A
- 4/9/26 - Form SCHEDULE
- 3/27/26 - Form SCHEDULE
- PCRX's page on the SEC website